Selected article for: "clinical trial and disease virus"

Author: Mok, Hoyin; Cheng, Xing; Xu, Qi; Zengel, James R; Parhy, Bandita; Zhao, Jackie; Wang, C. Kathy; Jin, Hong
Title: Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350
  • Document date: 2012_2_16
  • ID: 3qdjmb2j_37
    Snippet: The cotton rats immunized with MV expressing RSV F were also challenged with wt RSV. After challenge, the number of IFN-secreting cells was higher than IL-4 secreting cells, which was consistent with a Th1-biased response (data not shown). RSV enhanced disease has been associated with FI-RSV vaccine [54, 55] . A chimeric parainfluenza virus vectored RSV F [35] did not cause enhanced disease in hamsters and has been proven to be safe in phase I cl.....
    Document: The cotton rats immunized with MV expressing RSV F were also challenged with wt RSV. After challenge, the number of IFN-secreting cells was higher than IL-4 secreting cells, which was consistent with a Th1-biased response (data not shown). RSV enhanced disease has been associated with FI-RSV vaccine [54, 55] . A chimeric parainfluenza virus vectored RSV F [35] did not cause enhanced disease in hamsters and has been proven to be safe in phase I clinical trial in seronegative children [56] . Recently, a report from another group has shown that measles virus vectored RSV F did not cause unusual pathology in cotton rats after RSV challenge, thus, the likelihood of the MV vector F to cause enhanced disease is very low [15] .

    Search related documents:
    Co phrase search for related documents
    • clinical trial and enhanced disease: 1, 2, 3, 4, 5, 6, 7, 8
    • clinical trial and group report: 1, 2, 3, 4, 5, 6
    • clinical trial and parainfluenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • enhanced disease and FI RSV vaccine: 1